Financing the Future of Health: Navigating Biotech Investment Risks and Rewards with David Crean, Cardiff Advisory LLC & 1004 Venture Partners

About the Interviewee

David H. Crean is a Managing Partner at Cardiff Advisory LLC and a Partner at 1004 Venture Partners.

David H. Crean, B.Sc., M.Sc., Ph.D., MBA is Managing Partner of Cardiff Advisory LLC, Partner at 1004 Venture Partners, Chief Business Officer at MediciNova, Inc. (NASDAQ: MNOV), Forum Leader at REF, and Co-Founder & Forum Leader of CEOthreesixty. Over a 30-year career at the intersection of biopharma, healthcare services, and capital markets, he has earned a reputation for converting science-driven opportunity into measurable enterprise value. As an investor, operator, and board member, Dr. Crean focuses on innovations that extend healthspan—particularly in neurodegeneration—while architecting transactions that align clinical milestones with capital efficiency. Across these roles, he integrates upstream R&D insight with rigorous deal execution to help founders navigate inflection points, accelerate growth, and achieve value-creating exits.

At Cardiff Advisory, Dr. Crean leads a specialized M&A and corporate finance practice dedicated to healthcare and life sciences. He and his team advise founder-led and lower-middle-market companies on buy- and sell-side mandates, licensing, divestitures, capital raises, and strategic partnerships. A registered representative of BA Securities, LLC (Member FINRA/SIPC), he brings disciplined process management to every engagement—from valuation and diligence through negotiation and close—ensuring that scientific promise, market timing, and investor expectations are tightly synchronized.

As Partner at 1004 Venture Partners, Dr. Crean backs pre-seed through Series A companies building the longevity economy. He prioritizes platforms with translational clarity and de-risking roadmaps—biotech tools, neuro-therapeutics, and enabling technologies—that can compound value through data-rich development. In parallel, as Chief Business Officer of MediciNova, he leads investor relations, corporate and business development, and communications, supporting a late-stage pipeline in inflammatory, fibrotic, and neurodegenerative diseases. His cross-functional remit ensures coherent portfolio storytelling to the capital markets while advancing partnering optionality.

Beyond principal investing and transaction advisory, Dr. Crean is a community builder. He serves as Forum Leader for Life Sciences & Healthcare at REF, moderating peer advisory boards for executives in the San Diego ecosystem, and co-founded CEOthreesixty, a moderated forum for early-stage founders focused on leadership, commercialization, and board readiness. His governance experience spans public and private companies and nonprofits, including roles with Connect, Cenna Biosciences, Paracrine, Biocom California (Chair, Capital Development), and prior directorships with Histogen, Phoenix Molecular Designs, and California Life Sciences. He has also contributed to the sector’s talent pipeline through mentorship with Venture Forward, Nucleate, and other programs, and by writing for industry platforms that inform global life-sciences leaders.

Earlier, Dr. Crean held senior investment-banking and operating roles that anchor his end-to-end perspective on value creation. As Managing Director at Objective Capital Partners, he led the firm’s national Healthcare & Life Sciences practice across strategy origination and deal execution. At Allergan, he directed corporate business development and project/portfolio management, guiding assets from preclinical through approval and commercialization while negotiating cross-border licensing and M&A in North America, Europe, and Asia. He began his career in clinical research and photodynamic-therapy development at Miravant Medical Technologies, supported by NIH SBIR funding as Principal Investigator, and completed postdoctoral work at Roswell Park Cancer Institute and the University of Toronto.

Dr. Crean holds a Ph.D. in Biophysics and an M.S. in Natural Sciences/Oncology from the University at Buffalo, and an MBA in Finance from Pepperdine University’s Graziadio Business School. He took engineering courses at The Ohio State University and earned a B.S. in Pre-Med & Sports Medicine from Canisius University, where he competed in Division I baseball. He maintains FINRA Series 79 and 63 licenses and has completed venture-investor programs with Venture University and Venture Institute.

Across investing, advisory, and governance, Dr. Crean’s strengths include venture formation, licensing and partnerships, M&A strategy, capital markets, valuation, board leadership, and investor relations. His through-line is outcomes-driven: pair scientific rigor with capital discipline, match milestones to financing arcs, and build durable companies that matter.

The Discussion

Lab to Liquidity: Balancing Science and Finance in Biotech Investing

[Engr. Dex Marco]: It’s such a pleasure to have you here with us, Dr. Crean. So, David, with over three decades across biopharma, venture capital, and corporate finance, you’ve seen both the innovation cycle and the capital markets evolve. How do you integrate your deep scientific understanding with your financial acumen when evaluating biotech ventures, especially those in early-stage neurodegeneration and longevity sectors?

[Dr. David]: Thank you for having me, Dex. I like to have an integrated approach that connects the scientific rigor of the underlying biology and science with a pragmatic, milestone-driven financial model. By coupling deep biological assessment with disciplined financial foresight, one can identify assets that not only have the potential for breakthrough impact but also the robust business strategy and capital plan to navigate the challenging translational journey.

My process involves a synthesis across three main pillars: scientific de-risking, strategic market assessment, and financial modeling for inflection points. Allow me to explain this a bit more in depth.

In early-stage life sciences companies, where basic science is rapidly evolving, my focus starts with the core biology.

What’s the Plausibility of the Mechanism of Action (MoA): I wish to go beyond the initial data to assess the biological validity of the therapeutic approach. For neurodegeneration, this means rigorously evaluating whether a target—like a novel pathway for neuroinflammation or a specific senolytic in longevity—addresses a primary, disease-driving pathology, not just a downstream effect.

What’s the Team’s Expertise: I prefer to perform deep due diligence on the scientific founders and management, ensuring they have the track record and specific expertise required to navigate the high failure rates common to these complex fields. This is often a better predictor of early success than the initial preclinical data alone.  You need to remember that most investors invest in people, first and foremost. This is a critical aspect of any diligence.

Translational Risk: I scrutinize the path from bench to bedside. For CNS-focused therapies, this includes a critical look at things like blood-brain barrier penetration and the use of validated biomarkers (e.g., specific blood-based markers for Alzheimer’s or aging) that can provide early signals of efficacy in human trials.

A strong scientific rationale must meet a realistic market opportunity, especially in areas with potentially disruptive, yet unproven, modalities.

First-Mover vs. Best-in-Class: It’s important to evaluate where the product stands relative to the competition, considering both established treatments and other pipeline assets. In a sector like neurodegeneration, which is finally seeing approvals, it’s critical to ask: does this asset truly offer a differentiated value proposition (e.g., better safety profile, easier administration, targeting a new patient sub-population, better reimbursement coverage, better pricing)?

Targeting the “Healthy Aging” Market: For longevity, which is a rapidly expanding but less defined market, it’s important to evaluate the commercial strategy. Is the focus on a therapeutic indication to treat an age-related disease or a wellness/supplement play? This fundamentally changes the regulatory, reimbursement, and commercial risk profile.

My financial acumen then translates the scientific de-risking into a clear, capital-efficient investment thesis.

Capital Efficiency & Non-Dilutive Funding: It’s important to stress-test the company’s projected cash runway and identify opportunities for non-dilutive funding, such as securing grants (e.g., NIH, private foundations), government incentives, or early strategic partnerships that help subsidize high-cost, high-risk early clinical work.  It’s always a good idea to run your own P&L and revenue projections as well.  Don’t just rely on the company’s projections as they can be highly skewed and uncalibrated.

Milestone-Driven Valuation: It’s important to avoid valuing companies solely on terminal value projections. Instead, I like to focus on identifying and funding to key clinical and operational inflection points—such as Phase 1 or 2 safety data or proof of concept, or successful target engagement data. This minimizes burn rate and provides clear opportunities to raise subsequent capital at a higher valuation.

Scenario Planning: Given the inherent scientific risk in these early-stage fields, It’s important to build financial models with multiple sensitivity analyses. This quantifies the financial impact of various scientific outcomes (e.g., partial vs. full efficacy, dose-limiting toxicities) on the projected financing rounds and eventual exit via IPO or M&A.

Intelligent Design: Rethinking the Structure of Clinical Trials

[Dex]: Mergers, acquisitions, and licensing deals continue to define competitive growth strategies in life sciences. At Cardiff Advisory, how do you assess which transactions create sustainable value, and what indicators guide your decision-making in identifying synergistic opportunities amid market volatility?

[Dr. David]: My overall decision-making is guided by a simple principle: The transaction must unlock a future state for the combined entity that is fundamentally and quantifiably superior to the sum of its parts, with the risk allocated appropriately through smart deal structuring. Mergers, acquisitions, and licensing deals are fundamentally about accelerating sustainable value creation that neither party could achieve on its own. At Cardiff Advisory, we assess value not merely on near-term cost synergies but on the ability of a transaction to achieve three critical outcomes: science-to-market acceleration, financial resilience, and strategic fit.

Cardiff Advisory employs a framework that integrates deep scientific and commercial diligence with rigorous financial modeling, particularly amid market volatility. Pipeline and technology synergies are the cornerstones of life sciences value creation. Sustainable value is created when the acquired asset de-risks or accelerates the acquirer’s existing pipeline. The deal must fill a genuine pipeline gap (e.g., adding an early-stage, high-potential asset to offset a looming patent cliff) or provide a differentiated technology platform (e.g., acquiring an AI-driven discovery engine or a novel delivery technology like a new Antibody-Drug Conjugate platform). For pre-commercial assets, we look for validated biological PoC—clinical data that clearly demonstrates the mechanism of action is working in humans, even if it’s only Phase I/II data. A clean PoC is a strong indicator of sustainable value, as it dramatically reduces R&D risk. Additionally, the IP portfolio must be broad, deep, and defensible against a volatile competitive and regulatory environment. Clear freedom-to-operate and a robust global patent strategy are non-negotiable.

Sustainable value may also mean a transaction must be accretive on a value-per-share basis and structured to withstand market shocks. In the case of early-stage life sciences investing, this is not the case in most instances.  Transactions are mainly dilutive for several years given the large investment and time that are required to bring the products to market. We evaluate the transaction’s impact on key metrics like Cash Flow per Share and Earnings per Share (EPS) within a 3-5 year horizon. The focus is on future revenue from the acquired asset outweighing the transaction cost. Amid volatility, transactions that create the most resilient value are often those that utilize milestone-driven earn-outs and contingent value rights (CVRs). These structures allow the acquirer to tie a significant portion of the purchase price to the future clinical and regulatory success of the asset, effectively sharing the development risk with the selling shareholders. In a tight capital market, larger firms with strong balance sheets are uniquely positioned to acquire undervalued, cash-poor biotech innovators. We look for targets whose market capitalization is significantly depressed relative to the risk-adjusted net present value (rNPV) of their lead asset(s).

The shifting healthcare economy (e.g., focus on value-based care, rise of generics, pressure on brand pricing) demands M&A that fortifies the commercial core. The clearest synergy is often the ability of a large acquirer to rapidly commercialize an asset by leveraging its existing global sales force, market access teams, and payer relationships. Sustainable value is created when the acquired product can hit peak sales faster and at higher margins under the new ownership. Deals must align with megatrends and areas of durable demand, such as Oncology, Immunology, Rare Diseases, Cardiometabolic disease, and Neurodegeneration. These areas typically exhibit higher pricing power, lower biosimilar penetration risk, and a high unmet medical need. We prioritize assets with a clear, though challenging, regulatory path and the potential for a strong reimbursement profile. In a shifting environment, a product that offers a dramatic improvement in patient outcomes (reducing long-term healthcare costs) is more likely to secure favorable coverage.

Risk Intelligence: Investment Discipline in an Uncertain Biotech Landscape

[Dex]: Given the current tightening of venture markets and rising capital costs, investors must navigate uncertainty with sharper precision. What frameworks or methodologies do you employ to evaluate risk-adjusted returns in early-stage biotech, and how has your approach evolved heading into 2026?

[Dr. David]: The evaluation of risk-adjusted returns in early-stage biotech must be a core discipline for an investor, especially in a tightening venture market. We primarily employ the Risk-Adjusted Net Present Value (rNPV) or discounted cash flow (rDCF) methodology, but the true precision comes from augmenting it with a de-risking indices and rigorous scenario-driven capital planning.  One should always look at precedent transactions and company comparables as well in deriving valuations.

rNPV (or rDCF) remains the gold standard, but we apply it with heightened conservatism, given today’s market reality of higher capital costs and stricter investor requirements. Our approach has evolved from merely calculating rNPV to actively stress-testing the components that drive it, ensuring investment discipline. We use an internal De-Risking Index to go beyond average industry Probability of Success (PoS) statistics. This is a proprietary rubric that scores an asset on non-quantitative factors to determine a more accurate, company-specific PoS based on clinical, regulatory, commercial factors, and intellectual property to name a few.

Lastly, in a market where “flat is the new up” for private valuations, we structure investment rounds differently to prioritize cash runway and capital efficiency. I only like to fund companies that can demonstrate a clear path to a minimum of 18-24 months of cash runway to reach a major value inflection point (e.g., Phase I completion, full Phase II data readout). Funding is explicitly tied to these pre-defined scientific and clinical milestones. I believe it is important to stress-test the investment thesis by running a “flat round” or “down round” scenario for the next financing. If the initial investment cannot still generate a viable return (e.g., 3-5x cash-on-cash return) even if the next round is flat or lower, the initial investment should be rejected. This protects against downside dilution risk.

This approach ensures that investments are made not just in great science, but in great, capital-efficient science with a durable business plan and path to a strategic exit in an environment demanding fiscal prudence.

The Longevity Revolution: Funding the Science of Healthy Aging

[Dex]: As Partner at 1004 Venture Partners, your portfolio emphasizes innovation in longevity and neurodegeneration. What trends are you seeing in technologies that extend healthspan rather than just lifespan, and how are investors differentiating between hype and genuinely translational science in this emerging sector?

[Dr. David]: As an investor and advocate in these areas, I am keenly focused on the paradigm shift from merely extending lifespan to radically improving the quality of life and healthspan—the period of life spent in good health, free from chronic disease. The key is in targeting the hallmarks of aging to treat age-related disease at its root cause.

We are seeing a convergence of transformative technology trends that promise to deliver genuine healthspan extension.  First is there are therapeutics targeting geroscience. These are the most high-risk, high-reward plays aiming for pharmaceutical-grade interventions to modify the aging process itself. For example, in epigenetic reprogramming using technologies like modified mRNA or gene therapy to safely “reset” the epigenetic clock, researchers are trying to effectively turn back the biological age of specific tissues without causing cell transformation. This is a foundational technology for reversing age-related decline. Secondly, there are diagnostics, biomarkers, and AI-driven personalization. The is driving our ability to measure biological age and demonstrate it as the critical factor that differentiates translational science from hype. The line between bold promise and rigorous science is often blurred. Venture investment firms discipline must be focused on translating molecular evidence into clinical relevance. Invest in the “Find Fast, Act Fast, Kill Early” philosophy by leveraging diagnostics to find disease or decline early, and deploying transformative therapeutics or tech to act decisively, thereby extending the duration of a patient’s healthy, independent life.

Capital Synergy: Building Investor Confidence through Scientific Rigor

[Dex]: Investor confidence often hinges on clarity, credibility, and communication. From your experience as Chief Business Officer at MediciNova and advisor to numerous boards, how do you ensure that scientific storytelling aligns with investor expectations without oversimplifying complex data?

[Dr. David]: My experience as a Chief Business Officer at MediciNova and as an operator within other life sciences companies, as well as in advising boards of directors taught me that investor confidence is built not by simplifying the science, but by translating it into a clear, de-risked financial roadmap. My role is to be the translator and custodian of credibility, ensuring that the scientific team and investment committee share a common, clear language of value creation.

Achieving capital synergy means building a narrative where the scientific rigor is the foundation of the business value. I use a three-pronged framework to ensure this alignment: Translational Narrative, Data Tiering, and Transparent Risk Communication.

The initial story must immediately bridge the gap between complex science and tangible investor benefit. Start with the problem defined in commercial terms (e.g., “The current standard of care for this patient population is inadequate, resulting in a $XXB cost to the healthcare system and a five-year mortality rate of 60%”). This frames the investment as a necessity, not an optionality. The science must then explain why your solution works where others failed. Rather than listing technical terms, use a clear analogy to explain the MoA’s unique competitive advantage (e.g., “Our compound acts as a molecular wrench that directly fixes the underlying pathology, unlike competitor drugs which only treat the symptoms”). I like to encourage entrepreneurs to tell a compelling story of how their approach is a painkiller rather than a vitamin. Lastly, every piece of data—preclinical or clinical—must be presented not as an isolated scientific fact, but as a de-risking event that accelerates the financial timeline. Show that successful animal data moves you from 10% to 20% PoS (Probability of Success), which justifies the next financing round.

Beyond the initial narrative, data tiering is important as there is a need to cater to specialist and generalist investors. You never oversimplify; you simply organize the information by depth of detail required.

Finally, investor confidence is not built on the absence of risk, but on the management team’s candid awareness and planning for it. I coach founders and management teams to lead the discussion with the three biggest risks they know of (e.g., clinical results, competitive landscape, manufacturing scalability). This demonstrates a sophisticated understanding of the business. If a clinical trial experienced a setback (a dose-limiting toxicity or a primary endpoint miss), we communicate the lesson learned and the strategic pivot immediately. Transparency, even about failure, builds trust far more than defensive silence.

Mentorship and Market Resilience: Shaping the Next Generation of Life Science Leaders

[Dex]: Through CEOthreesixty, REF, and your multiple mentorship roles, you’ve helped founders develop leadership maturity and capital discipline. What are the most common strategic blind spots you observe in early-stage biotech leaders, and how can mentorship accelerate both innovation and investor readiness?

[Dr. David]: In my professional opinion, mentorship is arguably the single most powerful accelerant in early-stage biotech, turning brilliant scientists into capital-disciplined CEOs. Through programs like CEO360, REF, and other peer-to-peer advisory programs, my focus is on quickly instilling the external, strategic perspective that founders often lack. The most common blind spot I observe is the translational disconnect, which manifests in two critical areas: The “Science-First, Market-Second” Blind Spot and the “Capital Inefficiency” Blind Spot.

Founders often remain anchored in the laboratory mindset, prioritizing the perfection of the science over the commercial viability of the drug product.  After all, it’s their “baby” that they gave birth to. They have siloed thinking. They focus intensely on the core technology (the “how”) but fail to define the Target Product Profile (TPP) through the eyes of the payer, the regulator, and the ultimate customer. They often neglect to ask what exact clinical data point (endpoint) will the FDA/EMA accept for approval? Does this drug offer a clinical benefit that justifies a premium price over the current standard of care? Incremental benefit often won’t secure premium reimbursement.

The “Capital Inefficiency” Blind Spot is a profound lack of capital discipline, exacerbated by the recent tightening of venture markets. Leaders often plan R&D as a single, uninterrupted flow, failing to build contingency funds or off-ramps. They don’t model for the inevitable delays (NIH funding gaps, regulatory hold, supply chain issues) that will drastically increase burn rate. They anchor their valuation expectations to the “bull market highs” of previous cycles of 2020-2021, failing to accept the current market reality where risk-adjusted valuation is now the rule. This resistance to realistic pricing leads to stalled fundraising and ultimately, failure to launch. Lastly, they hire expensive, senior executives too early based on impressive titles, rather than focusing on highly efficient, lean teams capable of hitting the next single, critical clinical milestone.

So how does mentorship accelerate innovation and investor readiness?

Mentorship, especially through peer-to-peer cohorts and trusted advisor networks, rapidly converts scientific vision into an executable business plan. A mentor acts as an investor proxy and brings an external perspective, forcing the founder to anticipate due diligence questions before they are asked. This shifts the focus from “Is my science correct?” to “Is my path to commercialization credible?” Experienced mentorship also drives focused decision-making. We enforce a “Trade-off” mindset. Instead of pursuing five pre-clinical indications, we compel the founder to select the one indication that offers the highest Probability of Success and the fastest path to a Phase I safety signal. This concentration of capital accelerates innovation by providing focused resources for the lead asset.

Mentors help build leadership maturity. Telling the “Why This, Why Us, Why Now” Story helps scientific founders translate their complex data into a concise investor pitch that highlights the unmet clinical need, the competitive advantage, the team, and the clear exit strategy. This is the leadership maturity required to secure funding.  Many first-time CEOs struggle with this aspect. In essence, mentorship provides the external GPS that helps leaders navigate the opaque landscape of regulatory hurdles and capital markets. It fosters capital discipline by teaching the founder that their primary job is to create measurable value inflection points with the minimum amount of capital necessary.

Looking Ahead: Defining Biotech Investment Strategies for 2026 and Beyond

[Dex]: As the intersection of AI, data science, and life sciences reshapes investment theses, where do you foresee the greatest opportunities for value creation? How will venture investors and advisory firms like Cardiff adapt to ensure long-term impact across health, technology, and capital ecosystems?

[Dr. David]: The confluence of AI, data science, and life sciences is the most significant disruptive force in our sector. The greatest opportunities for value creation lie not in the new therapeutics alone, but in the platforms that reduce the systemic risk, cost, and time of drug development. For 2026 and beyond, I foresee the maximum value accruing to companies that achieve “De-Risked Discovery and Precision Translation.”

The future of biotech investment is characterized by two high-value categories: 1) AI-native, de novo drug discovery platforms; and 2) digitizing clinical trials, patient selection, and regulatory processes. 

Value shifts from owning a successful single molecule to owning a platform that can predictively generate novel, developable molecules with a higher probability of success. The opportunity is in companies using Generative AI to design entirely de novo chemical structures and protein sequences optimized for specific properties (e.g., cell permeability, low toxicity, multi-target binding). This accelerates Target-to-Lead timelines from years to months, fundamentally lowering R&D cost and increasing the velocity of innovation. Additionally, companies leveraging AI to analyze massive amounts of proprietary human data (genomics, proteomics, real-world evidence) to identify validated disease targets are highly valued. This minimizes the risk of failure due to selecting the wrong target—historically the single biggest reason for drug failure.

The next major value leap will come from digitizing the most expensive and time-consuming part of the pipeline: clinical trials and regulatory strategy. AI platforms that use real-time patient data, synthetic control arms, and predictive analytics to optimize trial design, identify high-compliance patient cohorts, and forecast enrollment rates. This accelerates time-to-market and reduces the enormous cost of Phase II/III failures. Investing in diagnostics and devices (especially in neurodegeneration and longevity) that use AI to provide early, actionable biomarkers in blood or imaging. These allow for earlier intervention in at-risk patients, which is critical for maximizing therapeutic efficacy and securing payer reimbursement.

So how do Venture Investment firms adapt?

To maintain long-term impact, firms must transform from being capital providers to technology integrators and risk architects adapting components in areas such as talent and expertise, due diligence, investment strategies, and advisory roles for portfolio companies. Investment firms need to prioritize “Code and Science” more equitably to ensure our capital accelerates not just a single drug, but a sustainable, repeatable engine for health innovation.

Overall, our discussion in this interview is centered on defining an integrated investment and advisory strategy for the modern life sciences ecosystem, emphasizing the critical role of scientific rigor, capital discipline, and technological adaptation.

The five key themes that I covered are:

Integrated Investment: Science Meets Finance

The core of biotech evaluation is the holistic integration of deep scientific understanding with financial acumen. This is achieved by coupling scientific rigor (rigorous validation of the Mechanism of Action and assessment of translational risk to humans) with milestone-driven financial modeling. Investment decisions are structured to fund specific, pre-defined value inflection points—such as a clean Proof of Concept signals—to ensure capital is only deployed when scientific risk is incrementally de-risked.

Strategic M&A: Accelerating Sustainable Value

Sustainable value in M&A is created when transactions achieve Science-to-Market Acceleration, rather than just cost-cutting. We assess transactions based on:

Pipeline Synergy: Does the acquired asset fill a critical pipeline gap or provide a genuinely differentiated technology platform?

Risk-Shared Structuring: Amid market volatility, deals must utilize flexible instruments like milestone-driven earn-outs and contingent value rights (CVRs) to tie purchase price directly to the future clinical and regulatory success of the asset.

Risk Intelligence: Disciplined Capital Deployment

Investment discipline in a tight venture market requires moving beyond traditional metrics. Our approach augments the standard Risk-Adjusted Net Present Value (rNPV or rDCF) by:

De-Risking Index (DRI): Applying internal scores that adjust the Probability of Success based on non-quantitative factors like the presence of a validated human biomarker and the prior success of the scientific team.

Scenario-Driven Capital Planning: Mandatory stress-testing of cash runway against down-round scenarios to ensure the company can reach its next major milestone with a minimum of 18-24 months of cash runway.

The Longevity Revolution: Healthspan Focus

The focus of the longevity sector has decisively shifted to Healthspan Extension—the quality of life free from chronic disease. The greatest investment opportunities lie in Geroscience therapeutics that target the Hallmarks of Aging, such as Senolytics (clearing senescent cells) and Epigenetic Reprogramming. Hype is differentiated from translational science by demanding evidence from AI-enabled diagnostics that measure Biological Age Clocks and can provide early, actionable clinical biomarkers in human studies.

AI as a Strategic Imperative

The intersection of AI and life sciences presents the greatest opportunity for long-term value creation by reducing systemic R&D risk. The future will be defined by:

Firm Adaptation: Advisory and investment firms must adapt by becoming Technology Integrators who employ in-house AI/data science expertise to conduct deep due diligence on the quality, exclusivity, and regulatory defensibility of a company’s training data—the “digital IP.”

AI-Native Platforms: Investment will shift to companies using Generative AI to design de novo therapeutics and accelerate Target-to-Lead timelines.

Engr. Dex Marco Tiu Guibelondo, B.Sc. Pharm, R.Ph., B.Sc. CompE

Editor-in-Chief, PharmaFEATURES

Join Proventa International’s Clinical Operations and Clinical Trial Supply Chain East Coast USA Strategy Meeting at Hard Rock Hotel, San Diego, California, USA on the 11th of November 2025 to learn more about Cardiff Advisory LLC and 1004 Venture Partners.